Christine J. Barr, BSN, MPH

VP Pharmacovigilance/PASS Planning and Development
CorEvitas, LLC

Poster(s):

• (C-156) Nuances of Risk Window Selection for Evaluation of Acute Adverse Events
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (C-206) Real-World Prospective Data Assessing the Long-Term Safety of Abrocitinib Treatment in Adults with Moderate to Severe Atopic Dermatitis (AD): Over Two years of Experience from the CorEvitas AD Registry
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET